PSORIATIC ARTHRITIS: CLASSIFICATION, CLINICAL PRESENTATION, DIAGNOSIS, TREATMENT
https://doi.org/10.14412/1995-4484-2018-60-69
Abstract
soriatic arthritis (PsA) is a chronic inflammatory disease of the joints, spine and entheses from a group of spondyloarthritis (SpA), which is usually observed in patients with psoriasis (Ps). The diagnosis of PsA is based on the CASPAR criteria for psoriatic arthritis. The disease results from interactions between genetic, immunological and environmental factors. The main clinical manifestations of PsA include peripheral arthritis, enthesitis, dactylitis, and spondylitis. PsA must be differentiated from rheumatoid arthritis, gout, reactive arthritis, osteoarthritis, and ankylosing spondylitis. Due to the fact that PsA is a clinically heterogeneous disease, its activity is assessed using complex indices, by taking into account that the patient has arthritis, enthesitis, dactylitis, and spondylitis. The goal of treatment for PsA is to achieve remission or minimal activity of the main clinical manifestations of the disease, to slow down or prevent radiographic progression, to increase life expectancy and quality of life in the patients, and to reduce the risk of comorbidities, which is achieved through a wide range of drugs of different classes. Therapy should be chosen based on the clinical manifestations of PsA and comorbidities in the patients.
About the Authors
T. V. Korotaev
V.A.Nasonova Research Institute of Rheumatology.
Russian Federation
Moscow.
Russian Federation
Moscow.
Yu. I. Korsakova
V.A.Nasonova Research Institute of Rheumatology.
Russian Federation
Moscow.
Russian Federation
Moscow.
References
1. Gladman DD, Stafford-Brady F, Chang CH, et al. Longitudinal study of clinical and radiological progression in psoriatic arthritis. J Rheumatol. 1990;17:809-12.
2. McHugh NJ, Balachrishnan C, Jones SM. Progression of peripheral joint disease in psoriatic arthritis: a 5-yr prospective study. Rheumatology (Oxford). 2003;42:778-83. doi: 10.1093/rheumatology/keg217
3. Moll JM, Wright V. Psoriatic arthritis. Semin Arthritis Rheum. 1973;3:55-78. doi: 10.1016/0049-0172(73)90035-8
4. Zias J, Mitchell P. Psoriatic arthritis in a fifth-century Judean Desert monastery. Am J Phys Anthropol. 1996;101:491-502. doi: 10.1002/(SICI)1096-8644(199612)101:4<491::AIDAJPA4>3.0.CO;2-Z
5. Moll JM, Haslock I, Macrae IF, Wright V. Associations between ankylosing spondylitis, psoriatic arthritis, Reiter’s disease, the intestinal arthropathies, and Behcet’s syndrome. Medicine (Baltimore). 1974;53:343-64. doi: 10.1097/00005792-19740900000002
6. Taurog JD, Chhabra A, Colbert RA. Ankylosing spondylitis and axial spondyloarthritis. N Engl J Med. 2016;374:2563-74. doi: 10.1056/NEJMra1406182
7. Taylor WJ, Gladman DD, Helliwell PS, et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006;54:2665-73. doi: 10.1002/art.21972
8. Olivieri I, Padula A, D’Angelo S, Cutro MS. Psoriatic arthritis sine psoriasis. J Rheumatol. 2009; Suppl 83:28-9. doi: 10.3899/jrheum.090218
9. Eder L, Haddad A, Rosen CF, et al. The incidence and risk factors for psoriatic arthritis in patients with psoriasis: a prospective cohort study. Arthritis Rheum. 2016;68:915-23. doi: 10.1002/art.39494
10. Villani AP, Rouzaud M, Sevrain M, et al. Prevalence of undiagnosed psoriatic arthritis among psoriasis patients: systematic review and meta-analysis. J Am Acad Dermatol. 2015;73:242-8. doi: 10.1016/j.jaad.2015.05.001
11. Чамурлиева МН, Логинова ЕЮ, Коротаева ТВ. Выявляемость псориатического артрита у больных псориазом в дерматологической и ревматологической клинике. Современная ревматология. 2016;10(4):47-50 [Chamurlieva MN, Loginova EYu, Korotaeva TV. Detection rates of psoriatic arthritis in patients with psoriasis in a dermatology and rheumatology clinic. Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2016;10(4):47-50 (In Russ.)]. doi: 10.14412/1996-7012-2016-4-47-50
12. Michelsen B, Fiane R, Diamantopoulos AP, et al. A comparison of disease burden in rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis. PLoS One. 2015;10(4):e0123582. doi: 10.1371/journal.pone.0123582
13. Kotsis K, Voulgari PV, Tsifetaki N, et al. Anxiety and depressive symptoms and illness perceptions in psoriatic arthritis and associations with physical health-related quality of life. Arthritis Care Res (Hoboken). 2012;64:1593-601. doi: 10.1002/acr.21725
14. Tillett W, Shaddick G, Askari A, et al. Factors influencing work disability in psoriatic arthritis: first results from a large UK multicentre study. Rheumatology (Oxford). 2015;54:157-62. doi: 10.1093/rheumatology/keu264
15. Arumugam R, McHugh NJ. Mortality and causes of death in psoriatic arthritis. J Rheumatol. 2012;89 Suppl:32-5. doi: 10.3899/jrheum.120239
16. Buckley C, Cavill C, Taylor G, et al. Mortality in psoriatic arthritis – a singlecenter study from the UK. J Rheumatol. 2010;37:2141-4. doi: 10.3899/jrheum.100034
17. Ritchlin CT, Colbert RA, Gladman DD. Psoriatic Arthritis. N Engl J Med. 2017;376:957-70. doi: 10.1056/NEJMra1505557
18. Mease PJ. Psoriatic Arthritis: update on pathophysiology, assessement and management. Ann Rheum Dis. 2011;70 Suppl:77-84. doi: 10.1136/ard.2010.140582
19. Love TJ, Zhu Y, Zhang Y, et al. Obesity and the risk of psoriatic arthritis: a population-based study. Ann Rheum Dis. 2012;71:1273-7. doi: 10.1136/annrheumdis-2012-201299
20. Коротаева ТВ. Псориатический артрит: клиника, диагностика, патогенез, лечение, маркеры кардиоваскулярного риска. Москва: НПО «Медиа-Графика»; 2013. 309 с. [Korotaeva TV. Psoriaticheskii artrit: klinika, diagnostika, patogenez, lechenie, markery kardiovaskulyarnogo riska [Psoriatic arthritis: clinic, diagnosis, pathogenesis, treatment, markers of cardiovascular risk]. Moscow: NPO «Media-Grafika»; 2013. 309 p.]. ISBN 978-5-905541-02-5.
21. Khan M, Schentag C, Gladman DD. Clinical and radiological changes during psoriatic arthritis disease progression. J Rheumatol. 2003;30:1022-6.
22. Gladman DD, Ziouzina O, Thavaneswaran A, Chandran V. Dactylitis in psoriatic arthritis: prevalence and response to therapy in the biologic era. J Rheumatol. 2013;40:1357-9. doi: 10.3899/jrheum.130163
23. Brockbank JE, Stein M, Schentag CT, Gladman DD. Dactylitis in psoriatic arthritis: a marker for disease severity? Ann Rheum Dis. 2005;64:188-90. doi: 10.1136/ard.2003.018184
24. Kehl AS, Corr M, Weisman MH. Review: enthesitis: new insights into pathogenesis, diagnostic modalities, and treatment. Arthritis Rheum. 2016;68:312-22. doi: 10.1002/art.39458
25. Stoll ML, Zurakowski D, Nigrovic LE, et al. Patients with juvenile psoriatic arthritis comprise two distinct populations. Arthritis Rheum. 2006;54:3564-72. doi: 10.1002/art.22173
26. Colbert RA. Classification of juvenile spondyloarthritis: enthesitisrelated arthritis and beyond. Nat Rev Rheumatol. 2010;6:477-85. doi: 10.1038/nrrheum.2010.103
27. Gladman DD, Antoni C, Mease P, et al. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis. 2005;64 Suppl 2:14-7. doi: 10.1136/ard.2004.032482
28. Chandran V, Barrett J, Schentag NC, et al. Axial Psoriatic Arthritis: update on a longterm prospective study. J Rheumatol. 2009;36;2744-50. doi: 10.3899/jrheum.090412
29. Sieper J, van der Heijde D, Landewe R, et al. New criteria for inflammatory back pain in patients with chronic back pain: a real patient exercise by experts from the Assessment of SpondyloArthritis International Society (ASAS). Ann Rheum Dis. 2009;68:784-8. doi: 10.1136/ard.2008.101501
30. Kane D, Pathare S. Early psoriatic arthritis. Rheum Dis Clin North Am. 2005;31(4):641-57. doi: 10.1016/j.rdc.2005.07.009
31. Qureshi AA, Husni ME, Mody E. Psoriatic arthritis and psoriasis: need for a multidisciplinary approach. Semin Cutan Med Surg. 2005;24:46-51. doi: 10.1016/j.sder.2005.01.006
32. Prey S, Paul C, Bronsard V, et al. Assessment of risk of psoriatic arthritis in patients with plaque psoriasis: a systematic review of the literature. J Eur Acad Dermatol Venereol. 2010;24 Suppl 2:31-5. doi: 10.1111/j.1468-3083.2009.03565.x
33. Gottlieb A, Korman N, Gordon K, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol. 2008;58:851-64. doi: 10.1016/j.jaad.2008.02.040
34. Mease PJ. Assessing the impact of psoriatic arthritis on patient function and quality of life: lessons learned from other rheumatologic conditions. Semin Arthritis Rheum. 2009;38:320-35. doi: 10.1016/j.semarthrit.2008.01.003
35. Raychaudhuri SK, Chatterjee S, Nguyen C, et al. Increased prevalence of the metabolic syndrome in patients with psoriatic arthritis. Metab Syndr Relat Disord. 2010;8:331-4. doi: 10.1089/met.2009.0124
36. Li W-Q, Han J-L, Chan TA. Psoriasis and psoriatic arthritis and increased risk of incedent Crohn's disease in US women. Ann Rheum Dis. 2013 Jul;72(7):1200-5. doi: 10.1136/annrheumdis2012-202143
37. Ogdie A, Schwartzman S, Husni ME. Recognizing and managing comorbidities in psoriatic arthritis. Curr Opin Rheumatol. 2015;27:118-26. doi: 10.1097/BOR.0000000000000152
38. Gossec L, Smolen J, Gaujoux-Viala C, et al. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis. 2012;71(1):4-12. doi: 10.1136/annrheumdis-2011-200350
39. Mease PJ. Assessment tools in psoriatic arthritis. J Rheumatol. 2008;35:1426-30.
40. Gladman DD, Inman RD, Cook RJ, et al. International spondyloarthritis interobserver reliability exercise – the INSPIRE study: II. Assessment of peripheral joints, enthesitis, and dactylitis. J Rheumatol. 2007;34:1740-5.
41. Nell-Duxneuner VP, Stamm TA, Machold KP, et al. Evaluation of the appropriateness of composite disease activity measures for assessment of psoriatic arthritis. Ann Rheum Dis. 2010;69:546-9. doi: 10.1136/ard.2009.117945
42. Smolen JS, Breedveld FC, Schiff MH, et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology. 2003;42(2):244-57. doi: 10.1093/rheumatology/keg072
43. Ritchlin CT, Kavanaugh A, Gladman DD, et al. Treatment recommendations for psoriatic arthritis. Ann Rheum Dis. 2009;68:1387-94. doi: 10.1136/ard.2008.094946
44. Mumtaz A, Gallagher P, Kirby B, et al. Development of a preliminary composite disease activity index in psoriatic arthritis. Ann Rheum Dis. 2010;70:272-7. doi: 10.1136/ard.2010.129379
45. Helliwell PS, Fitzgerald O, Fransen J, et al. The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project). Ann Rheum Dis. 2013;72:98691. doi: 10.1136/annrheumdis-2012-201341
46. Saber TP, Ng CT, Renard G, et al. Remission in psoriatic arthritis: is it possible and how can it be predicted? Arthritis Res Ther. 2010;12(3):94-8. doi: 10.1186/ar3021
47. Coates LC, Helliwell PS. Validation of minimal disease activity criteria for psoriatic arthritis using interventional trial data. Arthritis Care Res (Hoboken). 2010;62:965-9. doi: 10.1002/acr.20155
48. Kavanaugh AF, Ritchlin CT. Systematic review of treatments for psoriatic arthritis: an evidence based approach and basis for treatment guidelines. J Rheumatol. 2006;33:1417-21.
49. Coates LC, Kavanaugh A, Mease PJ, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis Rheum. 2016;68:1060-71. doi: 10.1002/art.39573
50. Gossec L, Smolen JS, Ramiro S, et al. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis. 2016;75:499-510. doi: 10.1136/annrheumdis2015-208337
51. Nash P, Clegg DO. Psoriatic arthritis therapy: NSAIDs and traditional DMARDs. Ann Rheum Dis. 2005;64 Suppl 2:ii74-ii77. doi: 10.1136/ard.2004.030783
52. Kingsley GH, Kowalczyk A, Taylor H, et al. A randomized placebo-controlled trial of methotrexate in psoriatic arthritis. Rheumatology (Oxford). 2012;51:1368-77. doi: 10.1093/rheumatology/kes001
53. Kaltwasser JP, Nash P, Gladman D, et al. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum. 2004;50:1939-50. doi: 10.1002/art.20253
54. Mease PJ. Biologic therapy for psoriatic arthritis. Rheum Dis Clin North Am. 2015;41:723-38. doi: 10.1016/j.rdc.2015.07.010
55. Weitz JE, Ritchlin CT. Ustekinumab: targeting the IL-17 pathway to improve outcomes in psoriatic arthritis. Expert Opin Biol Ther. 2014;14:515-26. doi: 10.1517/14712598.2014.890587
56. McInnes IB, Sieper J, Braun J, et al. Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-ofconcept trial. Ann Rheum Dis. 2014;73:349-56. doi: 10.1136/annrheumdis-2012-202646
57. Mease PJ, van der Heijde D, Ritchlin CT, et al. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. Ann Rheum Dis. 2017;76:79-87. doi: 10.1136/annrheumdis-2016-209709
58. Kavanaugh A, Mease PJ, Gomez-Reino JJ, et al. Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis. 2014;73:1020-6. doi: 10.1136/annrheumdis-2013205056
59. Mease P, Genovese MC, Gladstein G, et al. Abatacept in the treatment of patients with psoriatic arthritis: results of a sixmonth, multicenter, randomized, double-blind, placebo-controlled, phase II trial. Arthritis Rheum. 2011;63:939-48. doi: 10.1002/art.30176
Review
For citations:
Korotaev T.V., Korsakova Yu.I. PSORIATIC ARTHRITIS: CLASSIFICATION, CLINICAL PRESENTATION, DIAGNOSIS, TREATMENT. Rheumatology Science and Practice. 2018;56(1):60-69. (In Russ.) https://doi.org/10.14412/1995-4484-2018-60-69
Views:
15269
Email this article 